Denmark has suspended vaccination with AstraZeneca due to possible thrombus effects. Italy has temporarily withheld vaccination with a batch of AstraZeneca as a precaution, following clotting problems in other European countries. The Norwegian authorities have also announced this Thursday the suspension of the AstraZeneca vaccine. But the European Medicines Agency said Thursday that it sees no problems.
“There is no indication that vaccination caused these conditions, which are not listed as side effects of this vaccine. The position of the EMA safety committee is that the benefits of the vaccine continue to outweigh its risks and the vaccine can continue to be administered as long as thromboembolic cases are being investigated. The EMA is already reviewing all cases and other conditions related to blood clots, reported after vaccination with the COVID-19 AstraZeneca vaccine “, states the EMA: “The number of thromboembolic cases in vaccinated people is not greater than that observed in the general population. As of March 10, 2021, 30 cases of thromboembolic events had been reported among about 5 million people vaccinated with the COVID-vaccine. 19 AstraZeneca in the European Economic Area “.RELATED
The Minister of Health, Carolina Darias, wanted, for her part, to transmit this Thursday a message of “prudence and tranquility” due to the suspension in Denmark of the administration of the AstraZeneca vaccine after registering “serious cases of thrombi”, reports Efe , something that has not happened in Spain.
“Blood clots in Denmark have not been confirmed to have been caused by the AstraZeneca vaccine”, said the British regulator
The Danish General Directorate of Health (SST), reports Efe, announced this Thursday the temporary suspension for 14 days of the AstraZeneca vaccine after registering “serious cases of thrombi” in some people who had received it. The authorities emphasize that at this time it cannot be concluded that there is a direct relationship between the vaccine and thrombi, as they explained in a statement. One of the investigated cases is related to a death.
The director of the SST, Søren Brostrøm, stressed that it is a pause and that there is “good documentation” that the AstraZeneca vaccine is “safe and effective”, but that the Danish authorities are forced to react to information of possible effects “of Denmark and other European countries”.
All appointments and invitations to request an appointment to receive this vaccine are suspended, and those who have already received the first dose will have to wait until further notice.
The Italian Medicines Agency (AIFA), for its part, has reported that this Thursday it has temporarily suspended vaccination with a batch of the pharmaceutical AstraZeneca as a precaution, following reports of coagulation problems diagnosed in several European countries.
The agency has explained in a statement, reports Efe, that after information about health problems detected in other European countries, it has blocked the inoculation of the doses of batch ABV2856.
The AIFA emphasizes that for now “no causal link has been established between the administration of the vaccine and these events” detected in other countries and that the necessary controls are being carried out, collecting the pertinent clinical documentation. The samples from this batch will be analyzed by the Italian National Institute of Health.
Estonia, Lithuania, Latvia and Luxembourg have also suspended immunization with doses from that particular batch, which was received by 17 European Union countries, including Spain, Poland, Malta, France and Greece, according to the EMA.
In this sense, the Norwegian authorities have also announced this Thursday that they are suspending the use of the AstraZeneca vaccine after the Danish decision. We will wait and see if there is any connection between the vaccine and these cases of thrombi, “said Geir Bukholm, director of infections at the Norwegian Public Health Institute (FHI).
Unlike its neighbors Norway and Denmark, Sweden has nevertheless refused to temporarily stop the use of this vaccine. “We believe that there is not a sufficient basis to discontinue vaccination with AstraZeneca,” said Veronica Arthurson of the Swedish Medicines Agency.